R9Q.F RECCE PHARMACEUTICALS LTD
- Market cap
- EUR 61.8M
- P/E
- -
- P/B
- 159.49x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is R9Q.F undervalued?
Graham numberThe Graham number of RECCE PHARMACEUTICALS LTD cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RECCE PHARMACEUTICALS LTD fundamental analysis
No fundamental analysis for RECCE PHARMACEUTICALS LTD yet.
RECCE PHARMACEUTICALS LTD stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RECCE PHARMACEUTICALS LTD
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical…
Full company profileRECCE PHARMACEUTICALS LTD financial statements
RECCE PHARMACEUTICALS LTD annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating Income | -12.6M | -17.2M | -22.1M | -28.0M | -23.2M |
| EBITDA | - | -12.7M | -16.5M | -19.9M | -13.0M |
| Net Income | -11.0M | -13.1M | -17.7M | -21.4M | -15.0M |
| EPS | -0.06 | -0.07 | -0.09 | -0.07 | -0.05 |
| Balance Sheet | |||||
| Total Assets | 12.6M | 2.60M | 6.62M | 12.4M | 8.53M |
| Total Liabilities | 2.56M | 5.14M | 15.9M | 15.5M | 25.3M |
| Shareholders' Equity | 10.1M | -2.59M | -9.52M | -3.05M | -16.7M |
| Cash & Short-term Investments | 11.6M | 1.56M | 4.62M | 10.4M | 2.69M |
| Cash Flow | |||||
| Capital Expenditure | 40.3K | 38.6K | 142K | 26.3K | 62.0K |
| Free Cash Flow | -9.05M | -12.7M | -13.2M | -20.5M | -9.95M |
| Ratios | |||||
| ROE | -109.2% | - | - | - | - |
| ROA | -87.0% | -503.6% | -267.0% | -172.6% | -175.4% |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
RECCE PHARMACEUTICALS LTD dividends
RECCE PHARMACEUTICALS LTD has not paid dividends in the last 5 fiscal years.
Who owns RECCE PHARMACEUTICALS LTD
- Insiders 40.66%
- Institutions 13.65%
- Public & others 45.69%
- Shares outstanding 306M
- Free float 220M
RECCE PHARMACEUTICALS LTD company profile
- Company name
- RECCE PHARMACEUTICALS LTD
- Ticker
- R9Q.F
- ISIN
- AU000000RCE5
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Governor Macquarie Tower, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9000 1907
- Website
- recce.com.au
About RECCE PHARMACEUTICALS LTD
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase III clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
RECCE PHARMACEUTICALS LTD management
9- Dr. John K. A. Prendergast Ph.D.Executive Chairman of the Board · born 1954
- Mr. James Hamilton-Bray Graham GAICDCEO, MD & Executive Director
- Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci)Chief Scientific Officer & Executive Director
- Dr. Justin WardHead of Chemistry, Principal Quality Chemist & Executive Director
- Mr. Arthur KollarasPrincipal Engineer & Head of Manufacturing
- Dr. Alan W. Dunton B.Sc., M.D.Chief Medical Advisor & Non Executive Director · born 1954
- Mr. Justin ReynoldsChief Financial Officer
- Mr. Daniel Astudillo B.A., B.Com., M.B.A.Head of Marketing
- Ms. Maggie NiewidokCompany Secretary